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Abstract: S-1 is a combination of three pharmacological compounds, namely tegafur, gimeracil, 
and oteracil potassium. Tegafur is a prodrug of 5-fluorouracil (5-FU), an oral fluoropyrimidine, 
and it has been developed as a replacement for infusional 5-FU therapy. S-1-based chemotherapy 
and the combination of S-1 and cisplatin are the most reasonable first-line standards for unre-
sectable advanced gastric cancer in Japan. However, the application of S-1 for gastric cancer 
has been delayed in Western countries. One reason for this delay is that the pharmacokinetics 
of tegafur is affected by polymorphisms in cytochrome P-450 2A6, and consequently 5-FU 
concentrations in the plasma are more likely to be elevated in patients from Western countries. 
Although the dose of S-1 was reduced compared with the approved dose in Japan, a global 
Phase III study reported similar results regarding overall survival between S-1 plus cisplatin 
and infusional 5-FU plus cisplatin arms. Significant safety advantages were observed in the S-1 
plus cisplatin arm compared with the infusional 5-FU plus cisplatin arm. S-1 plus cisplatin has 
become acceptable for Western countries, also, as a choice for unresectable advanced gastric 
cancer. Comparisons with capecitabine and combination of several targeting agents with S-1 
are expected in the future.
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Introduction
Gastric cancer is the second most frequent cancer-related cause of death. It is more 
prevalent in East Asia and Central and South America than in other countries. The 
incidence of gastric cancer worldwide is estimated to be 934,000 cases, accounting for 
an estimated 700,000 to 800,000 deaths annually. Approximately half of new gastric 
cancer cases occur in East Asia, including 41% in China and 11% in Japan.1,2
For unresectable advanced or recurrent gastric cancer, systemic chemotherapy 
has become the standard treatment, with the goal of therapy being to provide pal-
liation and prolong survival. Various randomized trials comparing 5-fluorouracil 
(5-FU) alone and the combination of 5-FU and other drugs have been performed to 
evaluate treatments.3–5 In the Japan Clinical Oncology Group 9205 trial, neither cis-
platin (also known as CDDP) plus 5-FU (CF) nor uracil and tegafur plus mitomycin 
produced a significantly superior overall survival than 5-FU alone (median survival 
time [MST], 7.3, 6.0, and 7.1 months, respectively), although response rate (RR) and 
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  progression-free survival (PFS) in the CF arm were better 
than those of 5-FU alone (RR: 34% vs 11%, median PFS: 
3.9 months vs 1.9 months).5 Consequently, 5-FU alone has 
been considered a reference arm for chemotherapy trials of 
unresectable gastric cancer in Japan. The CF regimen also 
did not prolong survival compared with survival obtained 
with 5-FU alone in a Korean study.4 However, CF has been 
considered the best reference arm in Western countries 
because RR and PFS in the CF arm were better than those 
of 5-FU alone. In Europe, triplet regimens have been utilized 
to improve survival. The superiority of the combination 
of epirubicin plus CF (ECF) over a combination of 5-FU 
plus doxorubicin plus high-dose methotrexate in terms of 
overall survival was demonstrated.6 MST of ECF was only 
8.9 months, and no study was conducted to evaluate the 
effect of the addition of epirubicin to CF. Therefore, it is 
difficult to state that the addition of epirubicin to CF has 
been established for unresectable gastric cancer. The V325 
trial compared docetaxel plus CF with CF alone, and indi-
cated a significantly prolonged overall survival.7 However, 
docetaxel plus CF still has limited acceptance as a standard 
treatment for unresectable advanced gastric cancer because 
of the small benefit on overall survival of 0.6 months and 
its toxicity profile.
Recently, oral fluoropyrimidines have been developed 
as replacements for infusional 5-FU therapy and they 
have been indicated for various advanced cancers such as 
colonic, breast, and gastric cancers. In 2011, the Committee 
for Medicinal Products for Human Use, a division of the 
 European Medicines Agency, issued an opinion recommend-
ing the approval of S-1 for treatment in adults with advanced 
gastric cancer when given in combination with CDDP. This 
review focuses on the history of S-1 development for chemo-
therapy for advanced gastric cancer, considering the ethnic 
differences between Western and Asian countries.
Ethnic differences between Western 
countries and Japan
There are many differences between Western countries and 
Japan regarding gastric cancer. In Japan, because of the high 
prevalence of gastric cancer, a nationwide mass screening 
system and endoscopy techniques have been developed. 
More than half of the gastric cancer cases in Japan are 
detected at an early stage, compared to 20%–30% cases in 
the United States.
The localization of gastric cancer, too, differs between 
Japan and Western countries. In Japan, the rate of 
  Helicobacter pylori infection is very high, and more than 
90% of the cases of gastric cancers are localized in   noncardiac 
regions; in addition, almost all are adenocarcinomas. 
  Conversely, the incidence of gastric cancers localized in the 
cardiac region and the gastroesophageal junction has been 
rapidly rising in Western countries, especially in the United 
States.8 Adenocarcinomas arising in Barrett’s esophagus can 
be classified either as gastroesophageal junction carcinoma 
or as esophageal carcinoma. Even squamous cell carcinoma 
in esophagus was eligible for inclusion in some clinical trials 
of gastric cancer in Western countries.
Several randomized trials were performed to evaluate 
treatments for metastatic gastric cancer worldwide. However, 
drug characteristics such as clearance by an enzyme with 
genetic polymorphisms and a steep dose-response curve will 
make differences in the safety and efficacy profiles more 
likely. Conversely, a lack of metabolism or active excretion, 
a wide therapeutic dose range, and a flat dose-response curve 
will reduce the possibility of ethnic differences.9 Many cyto-
toxic anticancer drugs are classified as belonging to the for-
mer type. Both docetaxel and tegafur, which are used to treat 
gastric cancer, are affected by enzyme activity. Docetaxel, 
for example, causes a high incidence of neutropenia in Asian 
patients because of lower cytochrome P-450 (CYP)3A5*3 
activity compared with that in Caucasian patients.10
Development of oral 
fluoropyrimidines
Oral fluoropyrimidines have been developed as inactive 
prodrugs of 5-FU that are absorbed intact through the gastro-
intestinal mucosa and are converted to 5-FU by one or more 
enzyme systems. 5-FU exerts its antitumor effects through 
several mechanisms, including inhibition of ribonucleic acid 
synthesis and function, inhibition of thymidylate synthase 
activity, and incorporation into DNA, leading to DNA strand 
breaks.11,12 When 5-FU is orally administered, extensive 
first-pass metabolism of 5-FU in the gastrointestinal wall 
and liver decreases 5-FU plasma levels and causes severe 
intestinal mucosal damage.13,14
The pharmacokinetics of oral fluoropyrimidines is simi-
lar to infusional 5-FU, but not bolus 5-FU. A meta-analysis 
comparing bolus infusion vs continuous infusion of 5-FU 
in patients with colorectal cancer revealed a small survival 
benefit (approximately 24 days) and significant toxicity for 
continuous infusion over bolus infusion.15 Specifically, con-
tinuous infusion was associated with far less myelosuppres-
sion than bolus administration (4% vs 31%), but continuous 
infusion was associated with more hand-foot syndrome than 
bolus administration (34% vs 13%).
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The primary and rate-limiting enzyme involved in 5-FU 
metabolism is dihydropyrimidine dehydrogenase (DPD). To 
prevent inactivation by first-pass metabolism in the liver, oral 
fluoropyrimidines have been developed together with inhibi-
tors of DPD. Genetic polymorphisms affect DPD activity, 
with 2%–4% of the population estimated to be deficient in 
the enzyme.16
S-1 (Taiho Pharmaceutical Company, Tokyo, Japan) is 
a combination of three pharmacological compounds (tega-
fur, gimeracil [CDHP], and oteracil potassium [Oxo]) in a 
1:0.4:1 molar ratio.17 Figure 1 shows the metabolic pathway 
of S-1. Tegafur [R,S-1-1(tetrahydrofuran-2-yl)-5-FU] is a 
prodrug that is mainly converted by liver enzyme CYP2A6 
to 5-FU. It is first hydroxylated to 5′-hydroxytegafur and 
eventually converted to 5-FU.18 CYP2A6 gene variants other 
than wild-type (CYP2A6*1) have been identified. The com-
bined frequencies of the alleles lacking or exhibiting reduced 
enzymatic activity for nicotine metabolism (*2, *4, *5, *7, 
*9, *10, *11, *17, *19, and *20) were reported to be 9.1%, 
21.9%, 42.9%, and 50.5% in Caucasian, African-American, 
Korean, and Japanese subjects, respectively.19 Japanese indi-
viduals also have lower expression of the CYP2A6 isozyme 
than Caucasian individuals.20 In patients with two variant 
alleles of CYP2A6 (*4, *7, and *9), the clearance of tegafur 
was 58% lower than that in patients with the wild-type or 
*1 variant allele.21 It is postulated that the higher efficacy 
of CYP2A6 is one of the causes of the more rapid conver-
sion of tegafur to 5-FU in Caucasian subjects, who achieve 
a higher area under the curve of 5-FU than Asians. CDHP 
is an inhibitor of DPD, which degrades 5-FU to inactive 
5-fluorodihydrouracil in the liver and prolongs the half-life of   
5-FU. CDHP is primarily cleared by the kidneys. In patients 
with renal insufficiency, CDHP renal clearance is decreased, 
and 5-FU exposure is, thus, increased.21 Renal function, as 
reflected by creatinine clearance, was the primary factor 
that influenced CDHP exposure and 5-FU exposure. Oxo 
inhibits the phosphorylation of 5-FU to fluorouridine 
monophosphate, an active intermediary metabolite of 5-FU, 
by orotate phosphoribosyltransferase in the gastrointestinal 
tract, thereby reducing the toxic effects of 5-FU to the 
gastrointestinal tract. However, the protective value of Oxo 
against 5-FU-induced diarrhea in humans is not well estab-
lished, because 5-FU can also be phosphorylated by uridine 
phosphorylase or thymidine phosphorylase, generating 
5-fluorodeoxyuridine monophosphate, and thus, resulting 
in diarrhea. By those mechanisms, this drug is designed 
to enhance the efficacy of tegafur and reduce the toxicity 
of tegafur in the gastrointestinal tract. Although CYP2A6 
  variants are associated with the pharmacokinetic variability 
of tegafur, CDHP is a key determinant in the pharmacokinetic 
variability of 5-FU.21 The tolerance to fluoropyrimidines 
themselves is believed to be different among United States, 
Europe, and East Asia, and it is speculated that high folic acid 
levels in the diet may be responsible for the weak tolerance in 
Western populations.22 The incidence of adverse reactions is 
also affected by the protective effect of Oxo. Consequently, 
adjustment of S-1 by screening of CYP2A6 polymorphisms 
has not been established.
Capecitabine (N4-pentyloxycarbonyl-5′-deoxy-
5-fluorocytidine) is another oral fluoropyrimidine. 
  Figure 2 shows the metabolic pathway of capecitabine. 
It is a prodrug of a 5-FU prodrug (doxifluridine) and is 
Tegafur
CYP2A6
CDHP DPD
Liver Gut
5-FU
OPRT
FUMP
Tumor and bone marrow
FUMP
Oxo
FUH2
Figure 1 Metabolism of S-1.
Abbreviations: 5-FU, 5-fluorouracil; CDHP, gimeracil; CYP2A6, cytochrome P450 2A6; DPD, dihydropyrimidine dehydrogenase; FUH2, 5-fluorodihydrouracil; FUMP, 
fluorouridine monophosphate; OPRT, orotate phosphoribosyltransferase; Oxo, oteracil potassium.
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designed to minimize the substantial local gastrointestinal 
toxicity of doxifluridine without decreasing its antitu-
mor efficacy. Capecitabine itself is inactive. It is reliably 
absorbed unchanged from the gastrointestinal tract, and 
then converted through three enzymatic reactions to 5-FU. 
It is first converted to 5′-deoxyfluorocytidine in the liver 
by carboxylesterase, and then converted to doxifluridine 
by cytidine deaminase, a ubiquitous enzyme found in the 
liver, plasma, and tumor tissue. The toxic intermediary com-
pound doxifluridine is then converted to 5-FU by thymidine 
phosphorylase, an enzyme that may be more abundant in 
tumors than in normal tissue, thus potentially resulting in 
tumor 5-FU concentrations that far exceed its plasma levels 
and greater antineoplastic effects with lower toxicity. The 
differences in the metabolic systems of these drugs affect 
the optimal doses and safety profiles among patients in dif-
ferent regions, although both S-1 and capecitabine are oral 
prodrugs of 5-FU.
S-1-based chemotherapy  
for unresectable advanced gastric 
cancer in Asia
S-1 has been developed mainly in Japan because the phar-
maceutical company producing S-1 is a domestic Japanese 
company and there are sufficient numbers of patients with 
gastric cancer in Japan for clinical trials. Phase II trials of 
S-1 monotherapy (40 mg/m2, twice a day, on days 1–28, every 
6 weeks) were conducted in Japan, and they reported an RR 
of 44%–54% in patients with advanced gastric cancer.23–25 In 
1999, the Japanese government approved this drug for treat-
ing gastric cancer on the basis of the results of two domestic 
Phase II trials. Before the results of a Phase III trial were 
available, the use of S-1 rapidly increased in clinical practice 
in Japan because of its high RR and its convenience of oral 
therapy as a substitute for infusional 5-FU therapy.
After S-1 was approved by the government, a Phase III 
trial comparing 5-FU alone (800 mg/m2 on days 1–5 every 
4 weeks), irinotecan plus CDDP (irinotecan: 70 mg/m2 on days 
1 and 15; CDDP: 80 mg/m2 on day 1, every 4 weeks), and S-1 
alone (40 mg/m2, twice a day, on days 1–28, every 6 weeks) 
was conducted in Japan (Japan Clinical Oncology Group 
9912). Both irinotecan plus CDDP and S-1 alone produced 
a significantly higher RR and longer PFS than the control 
arm of 5-FU alone (RR: 38% vs 28% vs 9%, median PFS: 
4.8 months vs 4.2 months vs 2.9 months). In terms of overall 
survival, this study demonstrated that S-1 was not inferior to 
5-FU monotherapy (MST: 11.4 months vs 10.8 months, hazard 
ratio: 0.83). However, there was no demonstration of the sig-
nificant superiority of irinotecan plus CDDP over 5-FU (MST: 
12.3 months vs 10.8 months; hazard ratio: 0.85).26 This Phase III 
trial established oral S-1 as a substitute for standard infusional 
5-FU therapy for unresectable gastric cancer in Japan.
Regarding S-1 combination therapy, a Phase I/II study 
of S-1 combined with CDDP (S-1: 40 mg/m2, twice a day, 
on days 1–21; CDDP: 60 mg/m2 on day 8, every 5 weeks) in 
patients with advanced gastric cancer was conducted, and it 
reported an RR of 76%, a median overall survival of 383 days, 
and tolerable toxicity.27 In the Randomized Phase III Study 
of S-1 Alone Versus S-1 Plus CDDP in Advanced Gastric 
Cancer (SPIRITS) trial, which compared S-1 monotherapy 
(40 mg/m2, twice a day, on days 1–28, every 6 weeks) with a 
combination of S-1 and CDDP (S-1: 40 mg/m2, twice a day, 
on days 1–21; CDDP: 60 mg/m2 on day 8, every 5 weeks), 
the combination arm yielded a significantly higher RR and 
longer PFS and overall survival than the control arm (RR: 
54% vs 31%, median PFS: 6.0 months vs 4.0 months, MST: 
13.0 months vs 11.0 months).28 Since the SPIRITS trial, 
the combination of S-1 and CDDP has been considered the 
standard first-line chemotherapy for unresectable advanced 
gastric cancer in Japan.
Capecitabine
CE
CD CD
TP
5-FU
Liver Tumor
5′-DFCR 5′-DFCR
5′-DFUR 5′-DFUR
Figure 2 Metabolism of capecitabine.
Abbreviations: CE, carboxylesterase; 5′-DFCR, 5′-deoxyfluorocytidine, 5′-DFUR, doxifluridine; 5-FU, 5-fluorouracil; CD, cytidine deaminase; TP, thymidine phosphorylase.
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A Phase III trial comparing S-1 plus irinotecan (S-1: 
40 mg/m2, twice a day, on days 1–21; irinotecan: 80 mg/m2 
on days 1 and 15, every 5 weeks) with S-1 alone (40 mg/m2, 
twice a day, on days 1–28, every 6 weeks) was also conducted 
in Japan.29 Although S-1 plus irinotecan achieved a longer 
median survival than S-1 monotherapy (MST: 12.5 months 
vs 10.5 months) and was well tolerated, it did not produce 
significantly superior overall survival.
Recently the results of a Phase III trial comparing S-1 
plus docetaxel (S-1: 40 mg/m2, twice a day, on days 1–14; 
docetaxel: 40 mg/m2 on day 1, every 3 weeks) with S-1 alone 
(40 mg/m2, twice a day, on days 1–28, every 6 weeks) con-
ducted in Japan and Korea was reported in abstract form.30 The 
combination of S-1 plus docetaxel did not meet the primary 
endpoint of overall survival (log-rank P = 0.1416, hazard ratio: 
0.88). Regarding the combination of S-1 with other cytotoxic 
drugs, CDDP only but not irinotecan and docetaxel, provided 
a significant additional benefit on overall survival.
In Japan and Korea, a randomized trial of 3-weekly vs 
5-weekly schedule of S-1 plus CDDP for advance gastric 
cancer is ongoing.31 The primary endpoint is PFS, and this 
study is designed to test the superiority (or noninferiority) of 
the 3-week regimen over the 5-week standard regimen.
S-1-based chemotherapy for gastric 
cancer in Western countries
Regarding the application of S-1-based chemotherapy in 
countries other than Japan, a Phase I trial was conducted 
in Caucasian patients in the United States to establish the 
maximum tolerated dose of S-1 plus CDDP.32 Patients 
received CDDP intravenously on day 1 and S-1 orally 
twice a day on days 1–21 every 4 weeks. At level 1, the 
S-1 dose was 25 mg/m2 twice a day, but it was increased by 
5 mg/m2 per dose for the next level. CDDP was administered 
at 75 mg/m2 (for levels 1 and 2), but was then reduced to 
60 mg/m2 (level 1A). Dose-limiting toxicities occurred at lev-
els 1A and 2, and the most common dose-limiting toxicities 
observed at the maximum tolerated dose were fatigue, diar-
rhea, and diarrhea-associated dehydration. In this study, the 
area under the curve of 5-FU was significantly correlated 
with severe diarrhea. There was also a significant correlation 
between the area under the curve of cyanuric acid, an inactive 
metabolite of Oxo, and severe diarrhea. Although Oxo might 
be metabolized so rapidly to cyanuric acid that more Oxo 
might be necessary to prevent diarrhea in Western patients, 
the optimal dose of S-1 and CDDP in combination (S-1: 
25 mg/m2 twice a day, on days 1–21; CDDP: 75 mg/m2 on 
day 1) for Western patients has been defined (Table 1).
Using the Western dose of S-1 plus CDDP on the basis of 
the results of the Phase I trial, the combination was studied in 
a multicenter Phase II trial of untreated, advanced gastric or 
gastroesophageal adenocarcinoma patients in North   American 
and European institutions.33,34 The majority of patients (75%) 
were Caucasian and 15% were African-American and/or 
Latino. This study demonstrated that RR was 51% and MST 
was 10.9 months, and the combination of a reduced dose of 
S-1 plus CDDP exhibited a favorable toxicity profile.
The First-line Advanced Gastric Cancer Study (FLAGS) 
trial comparing an experimental regimen of S-1 plus 
CDDP (S-1: 25 mg/m2 twice a day, on days 1–21; CDDP: 
75 mg/m2 on day one, every 4 weeks) with a reference regimen 
of CF (5-FU: 1000 mg/m2 continuous infusion on days 1–5; 
CDDP: 100 mg/m2 on day 1, every 4 weeks) was conducted 
in 24 countries and 146 centers in the United States, Eastern 
and Western Europe, South America, Australia, and former 
Soviet Union nations.35 Eighty-six percent of the patients 
were Caucasian. African-American, Asian, American Indian, 
and Alaska Native patients each comprised less than 1.2% 
of the study population. The study was designed to confirm 
the superiority of overall survival in S-1 plus CDDP over 
CF (estimated MST was 10.5 months vs 8.5 months). MST 
was 8.6 months in the S-1 plus CDDP arm and 7.9 months 
in the CF arm (hazard ratio: 0.92, 95% confidence interval 
[CI]: 0.80–1.05, P = 0.20). RR was 29.1% for the S-1 plus 
CDDP arm and 31.9% for the CF arm. Median PFS was 
4.8 months (95% CI: 4.0–5.5 months) in the S-1 plus CDDP 
arm and 5.5 months in the CF arm (95% CI: 4.4–5.8 months). 
Primary endpoint was not achieved, and S-1 plus CDDP did 
not prolong overall survival compared with the findings for 
CF, although the overall survival was similar in both arms. 
Hematologic adverse events and treatment-related deaths 
were less common in the S-1 plus CDDP arm than in the 
CF arm, with neutropenia, thrombocytopenia, and leucope-
nia being significantly more frequent (Table 2). Median 
overall survival in the S-1 plus CDDP arm in the FLAGS 
Table 1 The optimal dose of S-1-based chemotherapy
Regimens Drugs Dose Cycle
S-1 alone S-1 40 mg/m2, twice a day,  
on days 1–28
6 weeks
S-1 + CDDP 
(Japanese dose)
S-1 40 mg/m2, twice a day,  
on days 1–28
5 weeks
CDDP 60 mg/m2 on day 8
S-1 + CDDP 
(western dose)
S-1 25 mg/m2, twice a day,  
on days 1–28
4 weeks
CDDP 75 mg/m2 on day 1
Abbreviation: CDDP, cisplatin.
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S-1 for adjuvant chemotherapy
In the Adjuvant Chemotherapy Trial of S-1 for Gastric 
Cancer study, the S-1 arm had a higher proportion of overall 
survival than the surgery-only arm in Japan.36 Patients with 
stage II or III gastric cancer who underwent curable gast-
rectomy with extended (D2) lymph-node dissection were 
included. S-1 was administered at 40 mg/m2 twice a day for 
4 weeks every 6 weeks and continued for 1 year. However, it 
is not easy to apply this result to other countries. Regarding 
gastrectomy, D2 dissection is the standard surgical technique 
used in Japan, whereas D1 dissection is used in Western 
countries. Two European randomized trials that compared 
D1 and D2 gastrectomy failed to demonstrate any survival 
benefit of D2 over D1.37,38 This failure was attributed to the 
10% higher mortality rate in the D2 arm. A large randomized 
trial comparing D2 dissection with D2 plus paraaortic nodal 
dissection (Japan Clinical Oncology Group 9501) revealed 
no significant survival benefit of D2 plus paraaortic nodal 
dissection over D2, but the 5-year survival and hospital mor-
tality rates were approximately 70% and 0.8%, respectively.39 
These differences in prognosis after surgery could affect the 
evaluation of adjuvant chemotherapy for gastric cancer.
Development of capecitabine-based 
chemotherapy
A randomized noninferiority trial comparing capecitabine plus 
CDDP (XP) (1000 mg/m2 twice a day on days 1–14; CDDP: 
80 mg/m2 on day 1) with CF (5-FU: 800 mg/m2 per day on days 
1–5; CDDP: 80 mg/m2 on day 1) demonstrated that XP was not 
inferior to CF in terms of PFS. Median PFS and median overall 
survival were 5.6 months and 10.5 months in the XP arm and 
5.0 months and 9.3 months in the CF arm, respectively.40
Table 2 Adverse events of First-line Advanced Gastric Cancer 
Study trial
Toxicity S-1 + CDDP  
(n = 521)
5-FU + CDDP  
(n = 508)
All 
(%)
Grades 3–4  
(%)
All  
(%)
Grades 3–4   
(%)
Anemia 81.6 20.7 78.1 20.9
Neutropenia 60.5* 32.3 82.5* 63.6
Thrombocytopenia 36.8* 8.3 50.5* 13.5
Leucopenia 54.9* 13.7 76.1 33.2
Febrile neutropenia 5.0* 14.4*
vomiting 48.0** 7.9 55.3** 9.6
Diarrhea 29.2* 4.8 38.4* 4.5
Hypokalemia 6.9* 3.6* 16.7* 10.8*
Stomatitis 6.3* 1.3* 30.3* 13.6*
Mucosal inflammation 3.8* 0.8* 29.9* 8.1*
Calculated  
CrCL ,50 mL/minute
22.6** 40.9**
All toxic deaths 2.5** 4.9**
Notes: *P , 0.01; **P , 0.05.
Abbreviations: 5-FU, 5-fluorouracil; CDDP, cisplatin; CrCL, creatinine clearance.
Table 3 Results of Phase iii trials of S-1-based chemotherapy
Study (region) Regiment Number  
of patients
RR (%) PFS (months) MST (months) P value
JCOG9912 
(Japan)
5-FU
CDDP +
irinotecan + S-1
234
236
234
9
38
28
2.9
4.8
4.2
10.8
12.3
11.4
 
NS
Noninferiority
SPiRiTS 
(Japan)
S-1
S-1 + CDDP
150
148
3
54
4.0
6.0
11.3
13.0
P , 0.05
GC0301/TOP-002 
(Japan)
S-1
S-1 + irinotecan
160
155
26.9
41.5
3.6
4.5
10.5
12.8
NS
START 
(Japan and Korea)
S-1
S-1 + docetaxel
313
310
18.4
30.3
4.0
4.7
11.7
13.0
NS
FLAGS 
(western)
S-1 + CDDP
5-FU + CDDP
521
508
29.1
31.9
4.8
5.5
8.6
7.9
NS
Abbreviations: 5-FU, 5-fluorouracil; CDDP, cisplatin; FLAGS, First-line Advanced Gastric Cancer Study; JCOG, Japan Clinical Oncology Group; MST, median survival time; 
NS, not significant; PFS, progression-free survival; RR, response rate; SPIRITS, Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer; 
START, Randomized Phase III Study of S-1 Alone Versus S-1 Plus Docetaxel in the Treatment for Advanced Gastric Cancer.
trial was shorter than that in the SPIRITS trial (8.6 months 
vs 13.0 months), although PFS was similar (4.8 months vs 
6.0 months) (Table 3). The reason may be associated with 
patient characteristics and medical infrastructure. In the 
SPIRITS trial, 65% of patients had target lesions and 74% 
of patients received second-line therapy. In the FLAGS trial, 
96% of patients had target lesions and only 31% received 
second-line therapy.
A Phase III study evaluating the superiority of S-1 
plus CDDP over CF is now in progress for diffuse gastric 
and esophagogastric junction cancers in the United States 
and European countries based on subgroup analysis of the 
FLAGS trial, which revealed better effect in patients with 
diffuse-type carcinoma.
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Similar results were observed in a randomized multi-
center Phase III study comparing capecitabine with FU and 
oxaliplatin with CDDP in patients with advanced esoph-
agogastric cancer.41 Patients received either triplet therapy 
with ECF or epirubicin plus XP or triplet therapy with 
epirubicin plus oxaliplatin plus FU (EOF) or epirubicin plus 
oxaliplatin plus capecitabine (EOX). All four regimens were 
administered every 3 weeks (epirubicin: 50 mg/m2 on day 
1; CDDP: 60 mg/m2 on day 1; oxaliplatin: 130 mg/m2 on 
day 1; capecitabine: 625 mg/m2 twice a day on days 1–21; 
5-FU: 200 mg/m2 on days 1–21). Median survival times in 
the ECF, epirubicin plus XP, EOF, and EOX arms were 9.9, 
9.9, 9.3, and 11.2 months, respectively. Noninferiority of 
the capecitabine group (epirubicin plus XP and EOX) to the 
FU group (ECF and EOF) and that of the oxaliplatin group 
(EOF and EOX) to the CDDP group (ECF and EOF) were 
confirmed. The toxic effects of capecitabine and FU were 
similar. These studies indicate that capecitabine can replace 
infusional 5-FU and that oxaliplatin can replace CDDP for 
patients with advanced gastric cancer.
Comparison of S-1 with  
capecitabine
A small Phase II study comparing S-1 (40 mg/m2 twice a day 
for 4 weeks every 6 weeks) and capecitabine (1250 mg/m2 
twice a day for 2 weeks every 3 weeks) in elderly patients with 
advanced gastric cancer in Korea revealed similar RR (28.9% 
vs 27.2%), time to progression (4.2 months vs 4.7 months), 
and overall survival (8.1 months vs 9.5 months) between the 
two arms.42 The incidence of grade 3–4 granulocytopenia 
was 4.8% with S-1 and 6.8% with capecitabine. Grade 3–4 
nonhematologic toxicities included asthenia (7.1% with S-1 
vs 9.1% with capecitabine), anorexia (9.5% vs 6.8%), diarrhea 
(0% vs 2.3%), and hand-foot syndrome (0% vs 6.8%).
Hand-foot syndrome appeared to occur more often in the 
capecitabine arm than in the S-1 arm for Asian patients with 
gastric cancer. However, studies comparing S-1 at a reduced 
dose and capecitabine have never been conducted in Western 
countries, and further studies are necessary to compare the 
efficacy and safety between these two drugs as replacements 
for infusional 5-FU therapy.
Combination with targeting agents
Recently, several Phase III trials with monoclonal antibodies 
for gastric cancer have been conducted around the world. 
A randomized trial comparing capecitabine or CF alone with 
capecitabine or CF plus bevacizumab as a first-line therapy 
failed to demonstrate the superiority of overall survival.43 
The overall survival of the reference arm was 12.1 months 
in Asia, 8.6 months in Europe, and 6.8 months in the United 
States. This may indicate that many important factors that 
affect survival, and thus, global studies combining popula-
tions from East Asia and other counties are not suitable for 
evaluating chemotherapy in gastric cancer patients.
A global randomized trial comparing 5-FU or capecitabine 
plus CF or XP plus trastuzumab based on the examination 
of human epidermal growth factor receptor-2 overexpression 
in gastric cancer tissues revealed a significantly superior 
overall survival of the trastuzumab combination arm (MST: 
13.8 months vs 11.1 months).44 Cytotoxic drugs were repeated 
every 3 weeks (capecitabine: 1000 mg/m2 on days 1–14 or 
5-FU: 800 mg/m2 on day 1–5; CDDP: 80 mg/m2 on day 1). 
Trastuzumab was repeated every 3 weeks (8 mg/kg initially 
followed by 6 mg/kg). This trial included 101 Japanese 
patients among 594 total patients, and all Japanese patients 
received the XP regimen with or without trastuzumab. Mainly 
on the basis of this study, the Japanese government approved 
capecitabine and trastuzumab in 2011. Both S-1 and capecit-
abine are available for advanced gastric cancer, and direct 
comparisons of S-1-based chemotherapy and capecitabine-
based chemotherapy are also expected in Japan.
The cetuximab in Combination with capecitabine and 
Cisplatin in Advanced Esophagogastric Cancer trial, which 
includes Japanese patients, is expected to define the role of 
cetuximab in combination with capecitabine and CDDP in 
the first-line setting for patients with advanced gastric or 
gastroesophageal junction adenocarcinoma. In Japan, a Phase 
II trial of cetuximab combination with S-1 plus CDDP is also 
ongoing. A randomized trial of EOX with or without panitu-
mumab for advanced and locally advanced esophagogastric 
cancer is currently ongoing in Europe.45
In East Asia, several Phase I/II studies of the combi-
nation of S-1 plus CDDP with targeting agents are being 
conducted. Sorafenib combined with S-1 plus CDDP was 
investigated in a Japan–Korea Phase I/II study, but high 
incidence of hand-foot syndrome was reported. Sunitinib is 
now being evaluated in combination with S-1 plus CDDP or 
XP in Japan. Aflibercept, a fusion protein that functions as 
an inhibitor of vascular endothelial growth factor, is under 
development worldwide, and two Phase I studies, one in 
combination with S-1 and another with docetaxel, are cur-
rently underway in Japan.
Conclusion
S-1 at a reduced dose can be an apt replacement for infusional 
5-FU therapy, even in Western countries. Moreover, safety 
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profiles were better in the S-1 plus CDDP arm than in the CF 
arm. Many regimens such as S-1 plus CDDP, XP, ECF, ECX, 
EOF, EOX, and docetaxel plus CF are available in Europe for 
patients with advanced gastric cancer. Additional effects of 
epirubicin or docetaxel on the combination of fluoropyrimi-
dine and platinum analog have not been established. Only 
trastuzumab has improved the efficacy of the combination 
of fluoropyrimidines and platinum analogs in patients with 
human epidermal growth factor receptor-2-positive advanced 
gastric cancer. Regimens should be chosen after considering 
the safety profile of the regimen, patient condition, and ease 
of administration. Further studies of S-1-based chemotherapy 
for gastric cancer will be expected both in Japan and   Western 
countries to determine the optimal first-line regimen for 
advanced gastric cancer.
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